Metastatic Colorectal Cancer: From Laboratory to Clinical Studies

Dear Colleagues,

Colorectal cancer (CRC) ranks third in terms of incidence among both men and women, and it is also the third most common cause of cancer-related death in the USA. It has always been acknowledged as a diverse disease, whose clinical course varies depending on the prognosis and response to treatment of each patient. Researchers and doctors are switching from a “one size fits all” approach to treating the disease to the identification of novel biomarkers that can be targeted to specifically treat each patient. The widespread use of next-generation sequencing techniques and liquid biopsies has enhanced our understanding of the molecular landscape of metastatic CRC. However, most patients with metastatic CRC need to receive treatment using a multimodal strategy that incorporates surgery, radiation, and chemotherapy/immunotherapy. Determining the molecular and cellular mechanisms underlying the onset and progression of this incurable cancer as well as the specific biomarkers connected to it will help with cancer detection and will improve prognosis. The core of tailored therapy in the twenty-first century is the multidisciplinary approach to the care of metastatic CRC, which combines fundamental and translational research with bedside clinical research. This Topic focuses on preclinical and clinical studies on metastatic CRC. We invite experts in molecular pathology, hematology–oncology, hematopathology, stem cells, immunotherapy, surgery, and other areas of cancer research to submit high-quality original studies or reviews related to the issues in this research area.

Dr. Ioannis Ntanasis-Stathopoulos
Dr. Diamantis I. Tsilimigras
Topic Editors